About the 1st NBPI Forum
The 1st Annual Neuroscience BioPartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. We anticipate around 200 delegates and 20 presenting companies. We will have our usual online One-2-One partnering system in place and meeting facilities.
Programme will feature sessions on:
Confirmed Keynotes include:
"New Directions for the Prevention and Reversal of Neurodegeneration" by Prof. Dr. Daniel Alkon CSO, Neurotrope BioScience "Transforming Translational Neuroscience" by Michael D. Ehlers Group SVP, Head, BioTherapeutics R&D, CSO, Neuroscience & Pain, Cambridge & Boston Site Head, Pfizer Inc. “Reinventing the Treatment of Dementia: A New Paradigm” by Vivek Ramaswamy Chief Executive Officer, Axovant Sciences Confirmed Speakers & Chairs Include:
Presenting Opportunities:
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 10 or 20 minute presentations. Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The New York forum provides the additional interaction with the academic/scientific and patient advocacy communities. To view confirmed presenting companies for 2016 forum click HERE Sponsorship and Exhibition:
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on + 44 203 463 4890 or by email: Silvia. |
Supported by:
Pharma Licensing Groups
Attending in 2016: Financial/Advisory/
Investors Attending in 2016 include: A C Binder Corp. Advent Healthcare Ventures Akemi Capital Altius Strategy Consulting APS International Athyrium Capital Management Barracuda Finance LLC BTIG, LLC CBT Advisors Chardan Capital Markets Clarus Ventures, LLC CornerstoneCapital AG CureDuchenne Ventures Dabar Investment Associates Defined Health Edison Group Excellentia Global Partners Gabelli & Company Grannus Securities JP Morgan Katan Associates, Inc. Ladenburg Thalmann Landmark Angels, Inc. Lauren Sciences, LLC Lexington Capital Management Lincoln Park Capital Little Gem Life Sciences Livingston Securities MayTech Capital Management MedImmune Ventures, Inc. MedPro Investors, LLC Mid Atlantic Bio Angels New Leaf Ventures NovaSecta Ltd. NSIP LLC NYSE Euronext OrbiMed Advisors, LLC Park Avenue Capital Piper Jaffray Ltd. Remiges Ventures Rockport Venture Partners Roth Capital Partners, LLC Stanphyl Capital Sternberg Investments SV Life Sciences Symmetry Capital Thomson Reuters Versant Ventures Vinart Corp. Capital Management Vomisa, LLC |